REBECCA RAMEY: Open Payments
NPI 1598005597 · WHITAKERS, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$547 in 29 payments from 15 companies in 2025. Trend: 2023 $376 · 2024 $827 · 2025 $547
Food & beverage: $547
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $126 |
| Novo Nordisk Inc | 5 | $83 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Amgen Inc. | 3 | $50 |
| Corcept Therapeutics | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Exact Sciences Corporation | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: TRELEGY ELLIPTA, JARDIANCE, OTEZLA, Rybelsus, Korlym, FARXIGA, Wegovy, VOQUEZNA.
Industry payments across NC — which companies pay providers there.
